{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:17:23Z","timestamp":1761862643389,"version":"3.33.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.urology.2006.12.010","type":"journal-article","created":{"date-parts":[[2007,3,22]],"date-time":"2007-03-22T10:59:14Z","timestamp":1174561154000},"page":"479-484","source":"Crossref","is-referenced-by-count":20,"title":["Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens"],"prefix":"10.1016","volume":"69","author":[{"given":"Chia-Chi","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chieh","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-How","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeong-Shiau","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2006.12.010_bib1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0022-5347(01)67598-0","article-title":"Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world","volume":"153","author":"Roth","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.12.010_bib2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2006.12.010_bib3","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.1990.8.6.1050","article-title":"A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors","volume":"8","author":"Logothetis","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2006.12.010_bib4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1200\/JCO.20.5.1361","article-title":"Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer","volume":"20","author":"Siefker-Radtke","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2006.12.010_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1200\/JCO.2004.02.152","article-title":"Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group","volume":"22","author":"Bamias","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2006.12.010_bib6","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2006.12.010_bib7","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1200\/JCO.1997.15.7.2564","article-title":"Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"15","author":"Saxman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2006.12.010_bib8","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2006.12.010_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urology.2006.12.010_bib10","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/cncr.21738","article-title":"Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity","volume":"106","author":"Lin","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2006.12.010_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.juro.2006.08.058","article-title":"Phase II trial of weekly paclitaxel, cisplatin plus infusional high-dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma","volume":"177","author":"Lin","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.12.010_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.urology.2006.12.010_bib13","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.urology.2006.12.010_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc"},{"key":"10.1016\/j.urology.2006.12.010_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/sim.4780040107","article-title":"The bootstrap and identification of prognostic factors via Cox\u2019s proportional hazards regression model","volume":"4","author":"Chen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.urology.2006.12.010_bib16","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2006.12.010_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2004.10.988","article-title":"The Phase III candidate: can we improve the science of selection?","volume":"22","author":"Bajorin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2006.12.010_bib18","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.bjc.6600886","article-title":"Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future","volume":"88","author":"Riley","year":"2003","journal-title":"Br J Cancer"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429506026343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429506026343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T04:30:51Z","timestamp":1736915451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429506026343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0090429506026343"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2006.12.010","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}